BTB06584 is a selective and IF1-dependentmitochondrial F₁F_o-ATPaseinhibitor without compromising ATP synthesis. BTB06584 can delays ischaemic cell death^[1].

Mitochondrial F₁F_o-ATPase^[1]

In HL-1 cells, BTB06584 (100 μM) inhibits F₁F_o-ATPase activity with no effect on the mitochondrial membrane potential (ΔΨm ) or O₂consumption. BTB06584 (100 μM) pretreatmet protects against ischaemic cell death in HL-1 cells prior to a period of ischaemia. ATP consumption is decreased following inhibition of respiration, and ischaemic cell death is reduced^[1].
BTB06584 efficiency is increased by IF1 overexpression and reduced by silencing the protein^[1].

BTB06584 (1 μM; 24 hours) treatment rescued defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants in which expression of the Atpif1a gene is lost. The concentrations of BTB06584 that restore haemoglobin biosynthesis also alter mitochondrial bioenergetics in living fish^[1].

417.82

Solid

C₁₉H₁₂ClNO₆S

219793-45-0

Room temperature in continental US; may vary elsewhere.

DMSO : ≥ 47 mg/mL(112.49 mM)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.98 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液